Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension. The study aims to assess the safety and effectiveness of ubrogepant, an investigational drug, in treating menstrual migraine, a condition causing severe headaches linked to the menstrual cycle.
The intervention being tested is ubrogepant, administered as oral tablets. It is designed for the short-term prevention of menstrual migraines, with participants receiving the drug or a placebo during the study’s double-blind period.
The study employs a randomized, sequential intervention model with quadruple masking to ensure unbiased results. Its primary purpose is treatment-focused, with participants and researchers unaware of group assignments.
The study began on September 10, 2024, with a primary completion date yet to be announced. The last update was submitted on July 29, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study could impact AbbVie’s stock performance and investor sentiment positively if successful, given the demand for effective menstrual migraine treatments. Competitors in the migraine treatment market may also feel pressure to innovate.
The study is ongoing, with further details available on the ClinicalTrials portal.